688,196 Shares in Moderna, Inc. $MRNA Acquired by Nuveen LLC

Key Points

• Nuveen LLC invested approximately $19.51 million in Moderna, acquiring 688,196 shares, representing 0.18% of the company.
• Institutional ownership of Moderna is significant, with hedge funds and other investors controlling 75.33% of its stock.
• Analysts have varied price targets for Moderna, with the consensus target at $43.59 and a range of ratings from Strong Buy to Sell.

Nuveen LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 688,196 shares of the company's stock, valued at approximately $19,510,000. Nuveen LLC owned 0.18% of Moderna as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Invesco Ltd. lifted its holdings in shares of Moderna by 17.5% in the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock valued at $166,801,000 after buying an additional 877,162 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Moderna by 28.8% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 659,250 shares of the company's stock valued at $18,690,000 after buying an additional 147,267 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Moderna by 12.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock valued at $74,557,000 after buying an additional 285,662 shares during the period. ASR Vermogensbeheer N.V. acquired a new stake in shares of Moderna in the first quarter valued at $614,000. Finally, Annis Gardner Whiting Capital Advisors LLC lifted its holdings in shares of Moderna by 38.4% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 7,529 shares of the company's stock valued at $213,000 after buying an additional 2,088 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Stock Performance

Shares of NASDAQ MRNA traded up $0.90 during mid-day trading on Friday, reaching $27.12. 9,158,832 shares of the company traded hands, compared to its average volume of 8,197,467. The stock has a market cap of $10.55 billion, a PE ratio of -3.60 and a beta of 1.83. The company's fifty day moving average is $29.18 and its two-hundred day moving average is $29.12. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $84.28.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The business had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. During the same quarter in the prior year, the firm posted ($3.33) EPS. The firm's revenue for the quarter was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. Research analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of recent analyst reports. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Barclays dropped their price target on Moderna from $40.00 to $31.00 and set an "equal weight" rating on the stock in a research report on Monday, August 4th. Leerink Partners dropped their price target on Moderna from $18.00 to $15.00 and set an "underperform" rating on the stock in a research report on Friday. Cowen initiated coverage on Moderna in a research report on Sunday, July 13th. They set a "hold" rating on the stock. Finally, UBS Group dropped their price target on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $42.88.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.